

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lal et al
U.S. Serial No. : 10/611,539
Filing Date : July 1, 2003
For : INHIBITORS OF CYCLIN DEPENDENT
KINASES AND THEIR USE
Group Art Unit : 1626

745 Fifth Avenue
New York, NY 10151

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed are copies of publications for the Examiner's review and consideration. Applicant respectfully requests that the Information Disclosure Statement ("IDS") filed electronically on September 19, 2006 in connection with this application, be disregarded and replaced with this IDS, filed electronically on September 20, 2006. Applicant inadvertently failed to pay the \$180 fee for submission of an IDS after receipt of an Office Action. Also, applicant mistakenly failed to submit the references in their complete form.

1. Schwartz et al, "Phase I Study of Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Paclitaxel in Patients with Advanced Solid Tumors", Journal of Clinical Oncology, Vol. 20, No. 8, April 15, 2002, pp. 2157-2170;

2. Tan et al, "Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients with Advanced Neoplasms", *Journal of clinical Oncology*, Vol. 20, No. 19, October 1, 2002, pp. 4074-4082;
3. Hirama et al, BLOOD, "Role of the Cyclin-Dependent Kinase Inhibitors in the Development of Cancer", *The Journal of The American Society of Hematology*, August 1, 1995, *Blood*, Vol. 88, No. 3, August 1, 1995, pp. 841-854;
4. Edward A. Sausville, "Cyclin-Dependent Kinases: Novel Targets for Cancer Treatment", *Developmental Therapeutics Program*, pp. 9-21;
5. Elsayed et al, "Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins", *The Oncologist*; 2001; 6: pp. 517-537;
6. Meier et al, "Properties and Potential Applications of Chemical Inhibitors of Cyclin-Dependent Kinases", *Pharmacol, Ther.*, Vol 82, Nos., 2-3, pp. 279-284, 1999;
7. Sausville et al, "Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target", *Pharmacol, Ther.* Vol. 82, Nos. 2-3, pp. 285-292, 1999;
8. Parker et al, "Early Induction of Apoptosis in Hematopoietic Cells Lines After Exposure to Flavopiridol", *The American Society of Hematology*", *Blood*, Vol. 91, No. 2, January 15, 1998; pp. 458-465.

We have enclosed a copy of PTO-1449 which is considered part of the Information Disclosure Statement. If a fee is required, the Examiner is hereby authorized to charge our Deposit Account 50-0320.

Applicant respectfully requests that the Examiner consider and make of record the documents cited herein and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants

By Howard C. Lee
Howard C. Lee
Reg. No. 48,104
Tel. (212) 588-0800

Based on Form PTO-1449
(3/96)

ATTY. DOCKET NO.

516745-2001.1

SERIAL NO.

10/611,539

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Lal et al

FILING DATE

July 1, 2003

GROUP

1626

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-----------------|------|------|-------|----------|-------------------------------|
| AA | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|----|-----------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| AB | | | | | | | |

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----|--|---|
| AC | | Schwartz et al, "Phase I Study of Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Paclitaxel in Patients with Advanced Solid Tumors", Journal of Clinical Oncology, Vol. 20, No. 8, April 15, 2002, pp. 2157-2170; |
| AD | | Tan et al, "Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients with Advanced Neoplasms", Journal of Clinical Oncology, Vol. 20, No. 19, October 1, 2002, pp. 4074-4082; |
| AE | | Hirama et al, BLOOD, "Role of the Cyclin-Dependent Kinase Inhibitors in the Development of Cancer", The Journal of The American Society of Hematology, August 1, 1995, Blood, Vol. 88, No. 3, August 1, 1995, pp. 841-854; |
| AF | | Edward A. Sausville, "Cyclin-Dependent Kinases: Novel Targets for Cancer Treatment", Developmental Therapeutics Program, pp. 9-21; |
| AG | | Elsayed et al, "Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins", The Oncologist; 2001; 6: pp. 517-537; |
| AH | | Meier et al, "Properties and Potential Applications of Chemical Inhibitors of Cyclin-Dependent Kinases", Pharmacol. Ther., Vol. 82, Nos. 2-3, pp. 279-284, 1999; |
| AI | | Sausville et al, "Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target", Pharmacol. Ther. Vol. 82, Nos. 2-3, pp. 285-292, 1999; |
| AJ | | Parker et al, "Early Induction of Apoptosis in Hematopoietic Cells Lines After Exposure to Flavopiridol", The American Society of Hematology, Blood, Vol. 91, No. 2, January 15, 1998, pp. 458-465. |

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.